{"id":881,"date":"2021-03-01T06:56:27","date_gmt":"2021-03-01T06:56:27","guid":{"rendered":"https:\/\/nclinnovations.org\/covid19monitor\/?p=881"},"modified":"2021-03-01T06:56:27","modified_gmt":"2021-03-01T06:56:27","slug":"26-feb-2021-antivirals-dual-drug-combination-produced-a-significantly-rapid-pcr-conversion-rate-to-negative-in-three-day-treatment","status":"publish","type":"post","link":"https:\/\/nclinnovations.org\/covid19monitor\/26-feb-2021-antivirals-dual-drug-combination-produced-a-significantly-rapid-pcr-conversion-rate-to-negative-in-three-day-treatment\/","title":{"rendered":"(26 Feb 2021) Antivirals- dual drug combination produced a significantly rapid PCR conversion rate to negative in three-day treatment"},"content":{"rendered":"<div class=\"boldgrid-section\">\n<div class=\"container\">\n<div class=\"row\">\n<div class=\"col-md-12 col-xs-12 col-sm-12\">\n<p class=\"\">A Randomized, Double-Blind, Multicenter Clinical Study Comparing the Efficacy and Safety of a Drug Combination of Lopinavir\/Ritonavir-Azithromycin, Lopinavir\/Ritonavir-Doxycycline, and Azithromycin-Hydroxychloroquine for Patients Diagnosed with Mild to Moderate COVID-19 Infections<\/p>\n<p>https:\/\/doi.org\/10.1155\/2021\/6685921<\/p>\n<p class=\"\">754 subjects participated in this study: 694 patients (92.4%) who presented mild symptoms and 57 patients (7.6%) classified as suffering from a moderate case of COVID-19. On the third day after treatment, 91.7%-99.2% of the subjects in Groups A-E were confirmed negative by a PCR swab test compared to 26.9% in the Control group. Observation of all groups which experienced a significant decrease in virus load between day 1 and day 7 was undertaken. Other markers, such as CRP and IL-6, were significantly lower in all treatment groups (p &lt; 0.05 and p &lt; 0.0001) than in the Control group. Furthermore, IL-10 and TNF-alpha levels were significantly elevated in all treatment groups (p &lt; 0.0001). The administration of azithromycin to the Control group increased CRP and IL-6 levels, while reduced IL-10 and TNF-alpha on day 7 (p &lt; 0.0001) compared with day 1. Decreases in ALT and AST levels were observed in all groups (p &lt; 0.0001). There was an increase in creatinine in the serum level of the Control, C, D, and E groups (p &lt; 0.05), whereas the BUN level was elevated in all groups (p &lt; 0.0001). The study findings suggest that the administration of lopinavir\/ritonavir-doxycycline, lopinavir\/ritonavir-azithromycin, and azithromycin-hydroxychloroquine as a dual drug combination produced a significantly rapid PCR conversion rate to negative in three-day treatment of mild to moderate COVID-19 cases.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>A Randomized, Double-Blind, Multicenter Clinical Study Comparing the Efficacy and Safety of a Drug Combination of Lopinavir\/Ritonavir-Azithromycin, Lopinavir\/Ritonavir-Doxycycline, and Azithromycin-Hydroxychloroquine for Patients Diagnosed with Mild to Moderate COVID-19 Infections https:\/\/doi.org\/10.1155\/2021\/6685921 754 subjects participated in this study: 694 patients (92.4%) who&hellip; <span class=\"read-more-span\"><a href=\"https:\/\/nclinnovations.org\/covid19monitor\/26-feb-2021-antivirals-dual-drug-combination-produced-a-significantly-rapid-pcr-conversion-rate-to-negative-in-three-day-treatment\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;(26 Feb 2021) Antivirals- dual drug combination produced a significantly rapid PCR conversion rate to negative in three-day treatment&#8221;<\/span> <span class=\"genericon genericon-next\"><\/span><\/a><\/span><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"bgseo_title":"","bgseo_description":"","bgseo_robots_index":"index","bgseo_robots_follow":"follow"},"categories":[82,6,4,9,12],"tags":[60,10,41],"_links":{"self":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/881"}],"collection":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/comments?post=881"}],"version-history":[{"count":1,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/881\/revisions"}],"predecessor-version":[{"id":882,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/881\/revisions\/882"}],"wp:attachment":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/media?parent=881"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/categories?post=881"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/tags?post=881"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}